Biomarker for river blindness discovered
Scientists at The Scripps Institute (California, USA) have used liquid chromatography?mass spectrometry (LC?MS) to identify a new biomarker for the diagnosis of river blindness.1
Scientists at The Scripps Institute (California, USA) have used liquid chromatography–mass spectrometry (LC–MS) to identify a new biomarker for the diagnosis of river blindness.1 The discovery is an important step towards the development of a portable diagnostic test for use in the field.
River blindness affects 37 million people worldwide and is focused specifically in sub-Saharan Africa, Central and South America and Yemen. The disease is caused by nematode (Onchocerca volvulus) larvae transmitted by blackfly (Simulium sp.). In an attempt to kill the larvae, the body mounts an inflammatory immune response, indirectly damaging the eye and other body tissues.
The team analysed the urinary metabolome of infected and uninfected patients, identifying one particular protein that became elevated in the urine of infected patients. High performance liquid chromatography (HPLC) was performed to concentrate the protein and LC–MS was able to identify the chemical structure as N-acetyltyramine-O,ß-glucoronide.
The analysis was not as straightforward as initially hoped. The small, then unknown, molecule was not immediately identifiable. Daniel Globisch, a postdoctoral fellow in the Janda laboratory, studied the available literature referencing the metabolome of the nematode and pinpointed the metabolite source. The molecule was a breakdown product of a neurotransmitter produced by young larvae, excreted into the urine at higher levels during an active infection.
“It’s a spectacular find in terms of biomarkers as it does not occur naturally in humans,” said Globisch. Lead investigator Professor Janda advanced on this stating that for the findings to be of value in Third World countries it would need to be developed into a portable instrument, “basically distilling our finding to a test that can be carted around in a backpack”.
According to the authors, the theory behind the investigation should be applicable to the diagnosis of other worm infection-induced diseases.
Reference
1. D. Globisch, A. Moreno, M.S Hixon, A.A.K. Nunes, J.R. Denery,S. Specht, A. Hoerauf and K.D. Janda, PNAS, DOI: 10.1073/pnas.1221969110 (2013).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
